Group 1 - The company, 巨子生物 (02367), announced a share buyback plan on December 18, 2025, involving an expenditure of HKD 13.883 million to repurchase 400,000 shares [1]

Group 1 - The company, Giant Bio (02367), announced a share buyback plan, intending to repurchase 400,000 shares at a cost of HKD 13.883 million [1]

表格類別： 股票 狀態： 新提交 公司名稱： 巨子生物控股有限公司 呈交日期： 2025年12月18日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02367 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | | ...

Core Viewpoint - The collagen market is undergoing significant changes with the approval of new products from Chongshan Bio and Aibai Rui, expanding the competitive landscape in the animal-derived collagen sector. The focus is shifting towards differentiation in terms of cost-effectiveness, brand recognition, product safety, and efficacy as the market becomes increasingly crowded [1][2]. Group 1: New Product Approvals - Chongshan Bio's new product is the world's first collagen implant with a concentration of 45mg/ml, aiming to establish a strong product image through high concentration [2]. - Aibai Rui's new product targets specific needs by improving cheek smoothness, attempting to create a niche in the market despite similarities to existing products [4]. Group 2: Market Dynamics - The animal-derived collagen market has formed an "eight strong" competitive landscape, with established players like Shuangmei Bio leading the market due to their early entry and established brand recognition [6]. - New entrants are focusing on differentiation strategies, such as high-quality ingredients and innovative product forms, to compete effectively [6]. Group 3: Growth of Recombinant Collagen - The recombinant collagen market is experiencing rapid growth, with a projected compound annual growth rate (CAGR) of 41.4% from 2023 to 2027, surpassing the 27.7% CAGR of animal-derived collagen [8]. - The market size for recombinant collagen products in 2023 is estimated at 28.63 billion yuan, slightly below the 29.79 billion yuan for animal-derived collagen, indicating a shift in consumer preference towards recombinant options [8]. Group 4: Competitive Landscape and Future Outlook - The approval of new recombinant collagen products is intensifying competition, with companies like Jinjian Bio and others entering the market, challenging the previous dominance of Jinbo Bio [9]. - The future of the collagen market will likely see increased competition, with a focus on cost-effectiveness, brand strength, and product efficacy becoming critical for success [12].

12月18日，受美股科技股集体下挫影响，港股今日维持低位震荡走势，截止收盘，恒生指数涨0.12%报 25498.13点，恒生科技指数跌0.73%报5418.29点，国企指数跌0.02%报8841.51点，红筹指数跌0.26%报 4049.62点。 盘面上，大型科技股走势分化，阿里巴巴跌1.3%，京东集团跌0.09%，小米集团跌2.47%，网易涨 0.67%，美团涨0.1%，快手涨0.23%，哔哩哔哩涨0.26%；航空股延续涨势，东方航空涨超7%；煤炭股 午后走强，汇力资源涨超9%；锂电池股跌幅居前，宁德时代跌超3%；新消费概念股走弱，名创优品跌 超3%；其他股票中，舜宇光学科技跌超1%；曹操出行跌超12%，恒大物业跌超9%，中国中免跌超 5%；上海复旦涨超7%，招金矿业涨超6%。 企业新闻 远大医药(00512.HK)：自主研发的重磅全球创新放射性核素偶联药物 GPN01530 在美国获批开展临床研 究。 和谐汽车(03836.HK)：附属iCar Group Limited可能通过引入新投资者开展进一步股权融资，涉资4000万 美元。 中国中车(01766.HK)：集团及下属企业近三个月合计签订约533.1 ...

Market Overview - The Hong Kong stock market opened lower but rebounded before closing down, with the Hang Seng Index falling by 0.44% to 25,357.69 points, the Hang Seng Tech Index down 1.26% to 5,389.3 points, and the National Enterprises Index down 0.6% to 8,790.55 points [1] - Major technology stocks experienced declines, including Alibaba down 1.58%, Tencent down 0.58%, and Xiaomi down 3.11% [1] - Airline stocks continued to rise, with Capital Airport increasing by over 7% [1] - Lithium battery stocks saw significant declines, with CATL down over 3% [1] - New consumption concept stocks weakened, with Pop Mart down over 2% [1] Corporate News - CICC (03908.HK) is planning a stock swap to absorb and merge with Dongxing Securities (601198.SH) and Cinda Securities (601059.SH), with resumption of trading on December 18 [2] - Ronshine China (03301.HK) reported a total contract sales of approximately 3.492 billion yuan for the first 11 months, a year-on-year decrease of 49.6% [3] - Wanbang Investment (00158.HK) reported revenue of 164 million HKD for the year ending September 30, 2025, a year-on-year increase of 1.6%, but a loss of 640 million HKD, widening by 309.61% [3] - Corning Jereh Pharmaceutical-B (09966.HK) had its IND application for JSKN027 officially accepted by the CDE [4] - China CNR (01766.HK) signed significant contracts totaling approximately 53.31 billion yuan over the past three months [5] - Bofull Property (00225.HK) reported a loss attributable to shareholders of 216 million HKD, a year-on-year decrease of 63.88% [6] - SenseTime (00020.HK) plans to issue shares at a discount of over 8% to raise approximately 3.15 billion HKD [7] - Minth Group (00425.HK) entered into a strategic cooperation agreement with a robotics company [8] - XunCe (03317.HK) is offering 22.5 million H-shares for subscription starting today until next Tuesday [9] - Budweiser APAC (01876.HK) appointed Bernardo Novick as CFO, effective April 1, 2026 [10] - China Metallurgical Group (01618.HK) plans to repurchase up to 2 billion A-shares and 500 million H-shares [11] - Kuaishou-W (01024.HK) repurchased 1.283 million shares for 83.037 million HKD at prices between 63.9 and 65.55 HKD [12] - Tencent Holdings (00700.HK) repurchased 1.057 million shares for 636 million HKD at prices between 595 and 605.5 HKD [13] - Techtronic Industries (00669.HK) repurchased 500,000 shares for 44.91 million HKD at prices between 89.35 and 90.50 HKD [14] - Country Garden Services (06098.HK) repurchased 3.697 million shares for 23.1748 million HKD at prices between 6.22 and 6.33 HKD [15] - Giga Bio (02367.HK) repurchased 400,000 shares for 13.9713 million HKD at prices between 34.62 and 35.22 HKD [16] Institutional Insights - According to CICC, the recent weakness in the Hong Kong market is attributed to southbound capital returning to A-shares due to new public fund benchmark regulations, concerns over IPO financing, and the upcoming peak of lock-up expirations [17] - Huatai Securities noted that while the market's downside is controllable, the upside potential remains limited, with sentiment indicators in a pessimistic range [18] - Ping An International expects the market to maintain a volatile trend in the short term, with investment strategies focusing on a "technology + dividend" barbell approach [18] - Jianyin International recommends buying on dips before the spring market in early 2025, focusing on high-yield stocks and sectors like technology, high-end manufacturing, and new energy [19]

Market Overview - The Hong Kong stock market opened lower on December 18, with the Hang Seng Index down 0.54% at 25,330.83 points, the Hang Seng Tech Index down 1.11% at 5,397.34 points, and the National Enterprises Index down 0.62% at 8,788.92 points [1] - Major tech stocks declined, including Alibaba down 1.99%, Tencent down 0.66%, JD.com down 0.8%, Xiaomi down 2.04%, NetEase down 0.86%, Meituan down 0.59%, Kuaishou down 1.69%, and Bilibili down 0.26% [1] - Automotive stocks weakened, with Xpeng Motors dropping over 2% [1] - Chinese brokerage stocks showed mixed performance, with China International Capital Corporation (CICC) rising over 7% while China Merchants Securities fell over 1% [1] Company News - China International Capital Corporation (CICC) is planning a stock swap to absorb and merge with Dongxing Securities and Xinda Securities, with resumption of trading on December 18 [2] - Ronshine China reported a total contract sales of approximately 3.492 billion yuan for the first 11 months, a year-on-year decrease of 49.6% [3] - Wanbang Investment reported revenue of 164 million HKD for the year ending September 30, 2025, a year-on-year increase of 1.6%, but a loss of 640 million HKD, widening by 309.61% [3] - Corning Jereh Pharmaceutical's IND application for JSKN027 has been officially accepted by the CDE [4] - Yanda Pharmaceutical's globally innovative radiopharmaceutical GPN01530 has been approved for clinical research in the U.S. [4] - China CNR Corporation signed approximately 53.31 billion yuan in major contracts over the past three months [5] - Bofull Property reported a loss attributable to shareholders of 216 million HKD, a year-on-year decrease of 63.88% [6] - SenseTime plans to issue shares at a discount of over 8% to raise approximately 3.15 billion HKD [7] - Minth Group has entered into a strategic cooperation agreement with a robotics company [8] - Xunce is offering 22.5 million H-shares for subscription starting today until next Tuesday [9] Institutional Insights - According to浦银国际, the Hong Kong stock market sentiment index has been volatile since November due to fluctuating expectations of U.S. Federal Reserve interest rate cuts and corrections in the U.S. AI sector. The forward P/E ratio of the Hang Seng Index is currently 12.7 times, down 5% from its highest point this year. In the absence of new catalysts, the market sentiment may enter a period of oscillation and repair, but a pessimistic outlook is not warranted. A rotation in short-term styles and investment themes is expected, with the "Tech + Dividend" barbell strategy remaining effective [17] - 银河证券 suggests that the government's policies aimed at "stabilizing growth and the stock market" will continue to shape sector trends. A moderately loose liquidity environment, ongoing capital market optimization, and the rebuilding of investor confidence are expected to drive the securities sector's upward momentum. The current environment is conducive to the acceleration of medium- to long-term capital entering the market, maintaining high market activity, and showcasing a "healthy bull" trend [18] - 中信建投 indicates that the securities sector is expected to experience continuous growth driven by favorable policies in 2026, with a new growth cycle beginning in 2025. However, brokerage stocks have underperformed due to a lack of independent catalysts and lingering pessimism from previous years. The three core favorable factors—serving new productive forces, medium- to long-term capital entering the market, and opportunities for brokerage internationalization—are not yet fully priced in by the market, but are expected to gradually materialize post-2026, providing solid support for medium- to long-term performance resilience [18]

Summary of Key Points from Conference Call Records Industry Overview - The conference call discusses the **large consumption sector**, highlighting the emergence of new consumer demands that drive growth in the sector through new products (personalized, green, low-carbon), new channels (snack chains, discount formats), and new business models (diverse consumption scenarios) supported by the "14th Five-Year Plan" [1][2]. Core Insights and Arguments - **Traditional Consumption Recovery**: The traditional consumption sector is expected to recover by 2026, driven by the release of residents' purchasing power and policy measures aimed at boosting employment and income stability. The food and beverage industry is stabilizing, with the liquor sector showing signs of fundamental stability and dairy products expected to recover quickly [1][5]. - **Commodity Market Trends**: The commodity market has shown a trend of high followed by low prices, with the government implementing various promotional policies to stimulate service consumption and domestic demand. The Ministry of Commerce has issued opinions to expand service consumption, aiming to enhance residents' quality of life and stimulate domestic demand potential [1][6][7]. - **Emerging Consumer Demands**: New consumer demands are impacting the large consumption sector through three main directions: the development of new products that meet diverse and personalized needs, the optimization of new channel structures, and the promotion of new business models that foster diverse consumption scenarios [2][4]. Important but Overlooked Content - **Social Services Sector Changes**: The social services sector is evolving to meet changing consumer demands, with slight increases in beauty care and retail sectors. Key areas of investment include outdoor sports, gold and jewelry, and cultural and trendy IPs, with recommendations for companies like Anta Sports and Lao Pu Gold [8][22]. - **Tourism Market Trends**: The tourism market is gradually recovering, with leading companies like Ctrip and Huazhu Group adapting through technological innovation and marketing to meet the new demands of both young and elderly consumers. China Duty Free's Hainan business has benefited significantly from new duty-free policies [9][10]. - **Food and Beverage Sector Stability**: The food and beverage sector is stabilizing, with the liquor market facing challenges but showing resilience in mass consumption. The snack sector is experiencing performance differentiation, while dairy product demand is steady and supply is gradually clearing [12][17]. - **Investment Opportunities in Agriculture**: The agriculture, forestry, animal husbandry, and fishery sectors present investment opportunities, particularly in pig farming and the pet industry, which is growing due to demographic changes and emotional needs [3][13][19]. - **Household Appliance Sector**: The household appliance industry is seeking structural highlights amid steady growth, with a focus on high-dividend white goods and improving profit margins in black goods. The market for robotic vacuum cleaners is also expected to grow due to technological advancements [20][21]. This summary encapsulates the key points discussed in the conference call, providing insights into the large consumption sector and its various components, along with potential investment opportunities and market trends.

自12月9日以来公司已连续7日进行回购，合计回购280.00万股，累计回购金额9859.74万港元。 其间该 股累计下跌3.57%。（数据宝） 证券时报·数据宝统计，巨子生物在港交所公告显示，12月17日以每股34.620港元至35.220港元的价格回 购40.00万股，回购金额达1397.13万港元。该股当日收盘价35.100港元，上涨1.09%，全天成交额1.62亿 港元。 | 日期 | 回购股数（万股） | 回购最高价（港元） | 回购最低价（港元） | 回购金额（万港元） | | --- | --- | --- | --- | --- | | 2025.12.17 | 40.00 | 35.220 | 34.620 | 1397.13 | | 2025.12.16 | 40.00 | 35.400 | 34.680 | 1402.61 | | 2025.12.15 | 40.00 | 35.240 | 34.440 | 1391.73 | | 2025.12.12 | 40.00 | 35.220 | 35.000 | 1403.64 | | 2025.12.11 | 40.00 | 35.360 | ...

巨子生物(02367)发布公告，于2025年12月17日该公司斥资1397.13万港元回购40万股，回购价格为每股 34.62-35.22港元。 ...